Wish you all a superb 2023. You get the grants you need, you publish the paper you want. More importantly, you and your love ones will be happy, and you make someone smile every day. Microbiology and the force will be with you.

Turkey needs your help❤️ #earthquake

Excited to share our work Sebastian Lourido presenting the first genome-wide survey of an apicomplexan parasite during infection of an animal host! #Toxoplasma #CRISPR biorxiv.org/content/10.110…

If you’re looking for real injustice, in the US, fewer than 10% of people with my cancer are killed by it. While, in many places, fewer than 10% of people survive it. It isn’t because they don’t have castor oil and turmeric. It’s because they don’t have chemo.

Good morning Johnson & Johnson. Today's gonna be a long day, admin, and I'm sorry about that, but we need your bosses to stop pursuing a secondary patent on bedaquiline and keeping six million people from being treated appropriately for multi-drug resistant tuberculosis. Video at noon.

Hank Green wake up buddy generic bedaquiline in almost every country with high rates of tuberculosis just dropped.

Johnson & Johnson claimed they needed to evergreen their bedaquiline patent to invest in new breakthrough therapies for tuberculosis. Well, Johnson & Johnson just ended all research and development into infectious disease. Despicable to claim R&D and then...abandon R&D.

Good morning, Danaher Corporation! Lovely day here in Indianapolis, and I hope it is for you as well. Today would be a great day to announce broader access to lifesaving TB tests through a price reduction for impoverished communities. It's #Timefor5 and time to put #PeopleOverProfits

I'm so proud to be part of an event in New York City later this week to discuss "Tuberculosis and its Discontents" with some of the world's leading authors and researchers. The event is FREE! Join us, New York! publichealth.nyu.edu/events-news/ev…

Ever wondered how to prioritize drug targets? Barbara's review on target vulnerability may give you some new ideas: doi.org/10.1111/nyas.1…

Weak links: Advancing target-based drug discovery by identifying the most vulnerable targets. New review by Barbara Bosch and colleagues. nyaspubs.onlinelibrary.wiley.com/doi/10.1111/ny…

Announcing the 2024 Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease buff.ly/4bHHdBR #bwfpath

Get geared up, TBFighters! 📢 Danaher Corporation missed the deadline to release the audit yesterday which means it's time to let them know how we feel about that choice....😤 tbfighters.org/audit #TimeFor5 #EndTB